Dr Reddys launch generic cancer drug in US market
Drug Firm Dr Reddy's Laboratories On Friday Said It Has Launched Its Generic Decitabine Injection Used In Treatment Of Cancer In The American Market After Receiving Approval From The US Health Regulator.
Drug firm Dr Reddy's Laboratories on Friday said it has launched its generic Decitabine injection used in treatment of cancer in the American market after receiving approval from the US health regulator.
The company has launched the Decitabine for injection in the strength of 50 mg in the US market following approval by the United States Food & Drug Administration (USFDA) of Dr Reddy's abbreviated new drug applications (ANDA), it said in a statement.
The company's product is generic version of Dacogen, manufactured and sold by Eisai Inc under license from Astex Pharmaceuticals Inc, it added.
"The Dacogen brand has US sales of approximately USD 260 million MAT (moving annual total) for the most recent twelve months ending in July 2013 according to IMS Health," Dr Reddy's said.
The company's Decitabine for injection 50 mg is available as a single dose vial, it added.
Dacogen is used in treatment of myelodysplastic syndromes and for acute myeloid leukemia.
Shares of Dr Reddy's Laboratories were today trading at Rs 2,327.10 per scrip in the afternoon trade on BSE, up 1.57 per cent from its previous close.
For all the Latest Business News, International News, Download News Nation Android and iOS Mobile Apps.
More from Business
Take Control Of Your Financial Goals: Apply For A Personal Loan Now
Nihal Dangoria: An Indian Entrepreneur Making a Bright Future For The Real Estate Industry
Data breach incident at Extramarks highlights growing cybersecurity concerns in Indian companies
How is ePayLater empowering retailers across the country
Follow your heart, but don't ignore your mind When it comes to investing